59441-32-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(1-Oxohexadecyl)-L-proline is used as a building block in the synthesis of peptides and proteins, contributing to the development of novel drugs with specific therapeutic properties. Its unique structure allows for the creation of bioactive peptides and proteins that can target various biological pathways and diseases.
Used in Drug Development:
1-(1-Oxohexadecyl)-L-proline is utilized as a key component in the design and synthesis of new pharmaceutical agents. Its potential biological activities, such as modulation of enzyme functions, make it a promising candidate for the treatment of various diseases, including those related to metabolic disorders and other pathophysiological conditions.
Used in Biological Research:
1-(1-Oxohexadecyl)-L-proline is employed as a research tool in biological studies, particularly in the investigation of enzyme functions and the development of therapeutic agents. Its unique structure allows researchers to explore its interactions with biological systems and understand its potential role in modulating biological processes.
Used in Lipid Metabolism Studies:
1-(1-Oxohexadecyl)-L-proline is studied for its potential role in lipid metabolism, as its hexadecyl group may influence lipid processing and transport within biological systems. Understanding its effects on lipid metabolism could lead to the development of new strategies for managing lipid-related disorders.
Used as a Precursor in Synthesis:
1-(1-Oxohexadecyl)-L-proline serves as a precursor for the synthesis of other bioactive compounds, expanding its utility in the creation of novel therapeutic agents and pharmaceuticals. Its unique structure provides a foundation for the development of new compounds with specific biological activities and therapeutic potential.

InChI:InChI=1/C21H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-20(23)22-18-15-16-19(22)21(24)25/h19H,2-18H2,1H3,(H,24,25)

Upstream product

• 14464-31-4 palmitic acid N-succinimide ester 
• 147-85-3 L-proline 
• 81912-43-8 rac.-3-hexadecanoyl-4-methoxycarbonyl-1,3-thiazolidine-2-thione 
• 57-10-3 1-hexadecylcarboxylic acid 
• 112-67-4 n-hexadecanoyl chloride 

Relevant academic research and scientific papers

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHOIPHILIC COMPOUNDS CONTAINING HYDRIPHOBIC RADICALS

A composition in the form of an injectable solution includes: amylin, an amylin receptor agonist or an amylin analog; at least one ionic species; and an amphiphilic compound having a hydrophilic skeleton HB, substituted by at least one hydrophobic radical -Hy according to formula (I). A composition further is characterised in that it also has prandial insulin. In one embodiment, the composition also has GLP-1, GLP-1 analogs, and GLP-1 receptor agonists, commonly called GLP-1 RA.

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid),X represents a cationic entity chosen in the group comprising alkali cations,Rb and Rb′, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R′b is a hydrophobic radical -Hy,Q and Hy are as defined above.n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5≤n+m≤250.

HUMAN MICROBIOTA DERIVED N-ACYL AMIDES FOR THE TREATMENT OF HUMAN DISEASE

The present invention provides compositions and methods for the modulation of G protein-coupled receptors (GPCRs). The invention provides a genetically engineered cell, wherein the cell expresses a human microbial N-acyl synthase (hm-NAS) gene. In one embodiment, the hm-NAS gene is N-acyl serinol synthase. The invention provides a probiotic composition, the probiotic composition comprises a genetically engineered cell of the invention. The invention provides a method for modulating a G protein-coupled receptor (GPCR) activity in a subject, the method comprises administering to the subject an effective amount of a composition comprising at least one selected from the group consisting of a genetically engineered cell, an hm-NAS gene, and a N-acyl amide.

Water soluble salts of lipidated peptides and methods for preparing and using the same

Provided herein are water soluble salts of Formula I, wherein R1, A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID

An injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: [in-line-formulae]?GpR?r?GpA?a?GpC)p ??I[/in-line-formulae] wherein the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition wherein it moreover comprises a prandial insulin.

Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME

Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

Luliberin analogues exhibiting a cytotoxic effect on tumor cells in vitro

Luliberin analogues modified at the N-terminus were synthesized to search for drugs exerting a cytotoxic effect on cells of hormone-dependent tumors. A synthetic scheme effective in the preparation of analogues containing fatty acid residues was proposed. The cytotoxic effect of the peptides was studied on a number of cell lines of human tumors in vitro. The dependence of the antitumor effect on the length of peptide chain, amino acid sequence, and structure of the N-terminal group was demonstrated. Modification with palmitic acid was found to result in highly active compounds in the case of analogues containing more than ten aa, whereas modifications with lauric, caproic, or trimethylacetic acid led to compounds with significantly lower activities. Analogues of luliberin containing a palmitic acid residue and effectively inhibiting the growth of tumor cells in vitro were synthesized. Pleiades Publishing, Inc., 2006.

Chiral surfaces in micelles of enantiomeric N-palmitoyl- and N-stearoylserine

Circular dichroism (CD) spectra were recorded with micellar aggregates of a series of N-palmitoyl and N-stearoyl derivatives of amino acid enantiomers. N-Palmitoyl- and N-stearoyl-L- (or -D-) serine in the micelle form (10-4 M in aqueous 0.01 M KOH) exhibited a strong CD band centered at 213-215 nm which could be completely abolished by disintegrating the micelles in 50% ethanol. Analogous CD spectra of enantiomeric N-palmitoyl derivatives of tyrosine or proline did not display any exclusive band for the micellar form. The CD spectra of the enantiomeric N-palmitoyl- or N-stearoylserine micelles presumably originated from a repetitive arrangement of the amide planes on the micellar surface. Computer modeling suggested an alternating tilt of the amide planes associated with the formation of parallel spines of -NH?OC- intermolecular hydrogen bonds which cover the micellar surface. Each of such spines has a supramolecular chirality, which is presumably the origin of the observed CD band. The network of such chiral spines forms a unique chiral surface which may bear important implications for surface recognition and catalysis.

A NEW DETERMINATION OF THE ABSOLUTE CONFIGURATION OF THE CHIRAL AMINE

A new method for assignment of the absolute configuration of the asymmetric carbon atom attached to an amino or imino group using rac.-3-hexadecanoyl-4-methoxycarbonyl-1,3-thiazolidine-2-thione (rac.-HDMTT) (4) is described.